Sunesis to Present at the 13th Annual BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, Calif., (February 8, 2011) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the upcoming 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 9:30 A.M. Eastern Time at the Waldorf Astoria Hotel in New York City.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Sunesis Pharmaceuticals Inc via Thomson Reuters ONE
Investor and Media Inquiries: Eric Bjerkholt David Pitts Sunesis Pharmaceuticals Inc. Argot Partners 650-266-3717 212-600-1902